Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
RESEARCH TOOLSreports
Holding TRDA?
Track your performance easily
TRDA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.75 - $18.17
Previous Close$14.55
Volume78.09K
Average Volume (3M)133.71K
Market Cap
$541.25M
Enterprise Value$420.44M
Total Cash (Recent Filing)$185.25M
Total Debt (Recent Filing)$64.44M
Price to Earnings (P/E)4.9
Beta0.79
Next Earnings
Nov 05, 2024EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.96
Shares Outstanding37,199,550
10 Day Avg. Volume101,461
30 Day Avg. Volume133,708
Standard Deviation0.25
R-Squared0.00237
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.26
Price to Sales (P/S)2.33
Price to Cash Flow (P/CF)3.50
P/FCF Ratio3.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.76
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda3.40
Forecast
1Y Price Target
$21.50Price Target Upside47.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Entrada Therapeutics Inc News
PremiumCompany Announcements
Entrada Therapeutics’ Promising Phase 1 DMD Drug Trial Results
Bulls Say, Bears Say
Bulls Say
Financial PerformanceFinancial results exceeded expectations with net earnings of $0.68 per diluted share versus the forecasted net loss.
Regulatory AdvancesCompany's Duchenne muscular dystrophy franchise continues to mature with upcoming regulatory submissions.
Strategic PartnershipsThe research and license agreement with Vertex for VX-670 shows a strategic partnership that could enhance Entrada's financial and developmental capabilities.
Bears Say
Financial PerformanceFull-year 2023 financial results reported a net loss greater than anticipated, with a revised full-year 2024 net loss estimate due to higher operating expenses.
Regulatory IssuesThe FDA issued a clinical hold on the IND submission for Entrada's lead candidate, ENTR-601-44, and the nature of the hold hasn't been disclosed.
Regulatory IssuesENTR-601-44 remains on clinical hold in the U.S. following communication from the FDA.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TRDA FAQ
What was Entrada Therapeutics Inc’s price range in the past 12 months?
Entrada Therapeutics Inc lowest stock price was $10.75 and its highest was $18.17 in the past 12 months.
What is Entrada Therapeutics Inc’s market cap?
Currently, no data Available
When is Entrada Therapeutics Inc’s upcoming earnings report date?
Entrada Therapeutics Inc’s upcoming earnings report date is Nov 05, 2024 which is in 46 days.
How were Entrada Therapeutics Inc’s earnings last quarter?
Entrada Therapeutics Inc released its earnings results on Aug 13, 2024. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $0.361 by $1.189.
Is Entrada Therapeutics Inc overvalued?
According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued.
Does Entrada Therapeutics Inc pay dividends?
Entrada Therapeutics Inc does not currently pay dividends.
What is Entrada Therapeutics Inc’s EPS estimate?
Entrada Therapeutics Inc’s EPS estimate is -$0.73.
How many shares outstanding does Entrada Therapeutics Inc have?
Entrada Therapeutics Inc has 37,199,550 shares outstanding.
What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?
Entrada Therapeutics Inc reported an EPS of $1.55 in its last earnings report, beating expectations of $0.361. Following the earnings report the stock price went up 11.26%.
Which hedge fund is a major shareholder of Entrada Therapeutics Inc?
Among the largest hedge funds holding Entrada Therapeutics Inc’s share is Baker Bros Advisors LP. It holds Entrada Therapeutics Inc’s shares valued at 69M.
---
Entrada Therapeutics Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.50 (47.77% Upside)
$21.50 (47.77% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.38%
12-Months-Change
Fundamentals
Return on Equity
32.80%
Trailing 12-Months
Asset Growth
17.81%
Trailing 12-Months
Company Description
Entrada Therapeutics Inc
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
---
TRDA Stock 12 Month Forecast
Average Price Target
$21.50
▲(47.77% Upside)
Technical Analysis
Best Analysts Covering TRDA
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+5.57%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +5.57% per trade.
---